Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL

Complete title: Phase I/II Study of Pembrolizumab in Combination with TG-1101 (Ublituximab) and TGR-1202 in Patients with Relapsed-Refractory CLL or Richter’s Transformation of CLL

Research Study Number 9727
 
Principal Investigator Mazyar Shadman
 
Phase I/II

Research Study Description

The purpose of this study is to evaluate the safety and effectiveness of pembrolizumab in combination with ublituximab and TGR-1202, in patients with advanced CLL.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 9727
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Hematologic Malignancies; Leukemia; Lymphoproliferative Disorders; Leukemia, Lymphoid; Immunoproliferative Disorders; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Immune System Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials